57 results about "Large intestinal" patented technology

This invention pertains to a method of promoting gastrointestinal health by ingesting a composition comprising one or more probiotic microorganisms, one or more carbohydrate sources, and one or more resistant protein products. Large intestinal health is benefited by one or more of the following: increased fecal weight, lower fecal pH, increased carbohydrate fermentation, and amelioration of protein fermentation.

In view of the finding that keeping a healthy body is fundamental for overcoming cancer, it is an object of the present invention to provide a nutritious composition that is effective in suppressing mutagenic substances and promoting good health. The composition also suppresses large intestinal cancer. The composition includes dietary fiber in a range of 15 wt % to 30 wt % in respect to the total amount of composition which is contained in dried koji fine powder that includes dead fungi of Aspergillus and active enzyme produced by the Aspergillus.

A tumor marker detection method, which is a tumor marker detection method for diagnosing colorectal cancer and colorectal adenoma comprising the following steps: a) collecting feces and freezing it; The step of homogenizing the frozen feces in the presence of the suspension to prepare the suspension; c) the step of extracting RNA from the obtained sample for RNA extraction; d) the step of reverse-transcribing the extracted RNA to obtain cDNA; e) a step of amplifying the obtained cDNA, and f) a step of detecting the amplified cDNA, characterized in that the tumor marker is at least one tumor marker selected from COX-2, SNAIL, and MMP-7 ( But exclude only any one of COX-2 or MMP-7).

To provide a microorganism and an ingredient thereof that contribute to prevention and treatment of immune diseases including allergy, autoimmune diseases and inflammatory bowel diseases (e.g., large-intestinal ulcer), a method of effectively selecting the microorganism, and a method of efficiently inducing immunoregulatory cells that play an important role on maintaining immunological homeostasis using the microorganism or the ingredient thereof. The present invention provides a Lactococcus and an ingredient thereof which induce production of IL-10 from mammalian dendritic or spleen cells, a method of obtaining the microorganism or the ingredient thereof by co-culturing a microorganism such as Lactococcus strains with mammalian dendritic or spleen cells to select a microbial cell having a high IL-10 production ability, a method of selecting the microorganism or the ingredient thereof by co-culturing an intestinal epithelial cell with a microorganism such as the lactic acid bacteria and selecting the cells on the basis of a caspase-1 activity and the ability of inducing the production of IL-18, and a food product or material and an animal feeding stuff or medical and pharmaceutical products which contain the lactic acid bacteria as an effective ingredient.

The invention discloses a pharmaceutical composition for treating constipation, which is prepared from the following raw materials in parts by weight: 3-4 parts of plantago polysaccharide, 8-10 parts of bee pollen, 2-4 parts of probiotic agent, konjac Glucomannan 1-2 parts, sodium alginate 1-2 parts, calcium chloride 1-2 parts. On the one hand, the konjac glucomannan added in the present invention can promote intestinal peristalsis; Sugar and sodium alginate are compounded to embed probiotics, which can avoid the inactivation of probiotics in the stomach and achieve the effect of probiotics colonizing the intestinal tract; in addition, plantago polysaccharides, bee pollen, and probiotic bacterial agents in the present invention , Konjac glucomannan cooperate with each other to soften the stool, promote gastrointestinal motility, restore the balance of intestinal flora, and achieve the effect of treating constipation from the root.

The present invention provides a class of compounds, which includes enantiomers and pharmaceutically acceptable salts thereof, that selectively and effectively inhibit Hakai-mediated ubiquitination, preferably without affecting Hakai protein levels, thereby representing excellent anti-cancer drugs useful in the treatment of a variety of cancers, such as carcinomas, in particular, tumors arising from the epithelial layers of the gastrointestinal track including month (oral cancer), esophagus, stomach, and small and large intestines (such as rectal or colon cancer). It also includes skin cancer, mammary gland (breast cancer), pancreas cancer, lung cancer, head and neck cancer, liver cancer, ovary cancer, cervix cancer, uterus cancer, gallbladder cancer, penile cancer, and urinary bladder cancer (such as renal, prostate or bladder cancer).